<\/p>\n
Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is changing.<\/p>\n
On Aug. 10, Britain’s medicines regulator cleared Lilly’s new daily pill for both weight management and type 2 diabetes. It was the first approval the drug received anywhere in Europe.<\/p>\n
The decision matters for anyone holding or watching Eli Lilly stock.\u00a0<\/p>\n
Lilly’s biggest growth bet has relied on injections. This approval gives it a pill version instead, one that patients take once a day.<\/p>\n
That shift could reach patients who never wanted a shot in the first place. And it puts Lilly head-to-head with its fiercest rival in a market that barely existed a year ago.<\/p>\n
Here is what the approval covers, why it could add millions of new customers, and what LLY investors should watch before deciding the news is fully priced into the stock.<\/p>\n
U.K. just approved Foundayo for Eli Lilly<\/p>\n
The drug is called Foundayo, and its active ingredient is orforglipron.\u00a0<\/p>\n
It is a once-daily pill that belongs to the same GLP-1 class as blockbuster injections like Mounjaro and Zepbound.<\/p>\n
GLP-1 drugs copy a gut hormone your body makes after eating. That hormone tells your brain you’re full, so you eat less.<\/p>\n
The U.K.’s Medicines and Healthcare products Regulatory Agencyauthorized Foundayo on Monday, Aug. 10, for adults with obesity, and for some overweight adults with a weight-related health condition, The Pharmacist reported.<\/p>\n
It also cleared the pill to help control blood sugar in people with type 2 diabetes. That dual approval widens the pool of patients who could qualify.<\/p>\n
The regulator was blunt about one limit, though. The tablet is approved for use, but it is not yet available on the National Health Service.<\/p>\n
Eli Lilly’s Foundayo is a once-daily pill that patients can take without food or water restrictions.<\/p>\n
jetcityimage / Getty Images<\/p>\n
Why Foundayo pill could reach patients whom injections never did<\/p>\n
For years, the biggest barrier to weight-loss drugs was not the science. It was the needle.<\/p>\n
Millions of people who could benefit from these treatments avoid them because of a fear of needles, the hassle of refrigerating an injector pen, or the discomfort of injecting themselves in public.<\/p>\n
A daily tablet removes most of those worries. That’s the core reason Lilly sees Foundayo reaching a new group of customers.<\/p>\n
Foundayo carries a second advantage that’s easy to overlook. Patients can take it at any time of day, with or without food or water.<\/p>\n
That may sound minor, but it isn’t for the rival product.\u00a0<\/p>\n
Novo Nordisk’s oral Wegovy must be swallowed on an empty stomach with a small sip of water, followed by a mandatory 30-minute wait before eating or drinking, Quartz reported.<\/p>\n
For a drug people take every single day for years, convenience determines whether they stick with it.<\/p>\n
What the Foundayo clinical data actually show<\/p>\n
Convenience only matters if the pill works, so the trial results are worth a close look.<\/p>\n
In Lilly’s ATTAIN-1 study, 3,127 adults with obesity took Foundayo for 72 weeks. Those on the highest dose lost an average of 11.2% of their body weight, EMJ reported.<\/p>\n
Related: Morgan Stanley uncovers major Bristol Myers stock signals<\/p>\n
More than half of patients on that dose lost at least 10% of their weight. The trial also showed improvements in heart-health markers, including cholesterol and blood pressure.<\/p>\n
Here’s the full context for investors:<\/p>\n
Foundayo’s results trail the injections. Lilly’s Zepbound averages about 21% weight loss.The pill’s advantage is reach and cost, not raw power.For patients who won’t inject, a pill that works reasonably well beats a stronger shot they’ll never take.<\/p>\n
That trade-off is exactly the bet Lilly is making.<\/p>\n
The competition problem Lilly can’t ignore<\/p>\n
Lilly does not walk into the U.K. market without competition. Novo Nordisk got there first with its own oral option.<\/p>\n
Novo’s Wegovy pill launched in Britain about two months before Foundayo’s approval, according to CNBC. That head start gives Novo an early base of patients and prescribers.<\/p>\n
The rivalry is intense enough that both companies are raising guidance and defending market share on every earnings call.\u00a0<\/p>\n
Novo Nordisk recently lowered what investors should expect from Wegovy pill sales, after posting a weaker quarter than Wall Street wanted.<\/p>\n
Foundayo’s U.S. debut showed the challenge clearly. The pill brought in $98 million in its first full quarter after launching in April, which came in slightly below what analysts expected.<\/p>\n
Lilly will need aggressive marketing to close Novo’s early lead in Britain.<\/p>\n
How Foundayo will reach U.K. patients, and the pricing question<\/p>\n
Foundayo will launch in the U.K. later this month through private prescription, meaning patients pay out of pocket at first.<\/p>\n
Lilly said the pill will cost less than Mounjaro, which lists at \u00a3330 for a month’s supply, Reuters reported. The company has not confirmed an exact figure yet.<\/p>\n
The bigger prize is public coverage, and that decision is out of Lilly’s hands.<\/p>\n
More Healthcare Stocks:<\/p>\n
BofA points to the Eli Lilly market that could outsize the U.S.Novo Nordisk CEO resets expectations for Wegovy’s explosive growthGoldman Sachs says one number will move Eli Lilly stock<\/p>\n
Before the NHS covers Foundayo, the National Institute for Health and Care Excellence must finish a cost-effectiveness review.\u00a0<\/p>\n
That verdict is due on Nov. 18, 2026, The Pharmaceutical Journal reported.<\/p>\n
A favorable ruling would unlock mass distribution across the U.K.\u00a0<\/p>\n
A rejection or a demand for steep discounts would limit near-term growth. Investors should treat that date as a real catalyst, not a formality.<\/p>\n
What LLY investors should watch next<\/p>\n
Foundayo is under review in the European Union, and a positive decision there would open a far larger market.<\/p>\n
Here are the three milestones worth tracking:<\/p>\n
Key Foundayo catalysts for 2026 and beyondU.K. private launch (late August 2026): First real read on demand and out-of-pocket pricingNICE reimbursement decision (Nov. 18, 2026): Decides whether the NHS covers Foundayo for wide public useEU approval (timing to be confirmed): Unlocks the broader European market<\/p>\n
Lilly stock rose about 3.9% to $1,231.94 on Aug. 10 after the news, near its 52-week high, Grafa reported.<\/p>\n
At a price-to-earnings ratio around 40, a lot of future growth is already built into LLY shares. That valuation leaves little room for error if a launch fails or NICE pushes back on price.<\/p>\n
If you own Lilly or are considering it, treat Foundayo as one pillar of a broad franchise rather than a single make-or-break product.\u00a0<\/p>\n
Size any position to your own risk tolerance, since a highly valued stock can drop sharply when expectations run this high.<\/p>\n
Lilly just gained legal access to a market of millions who avoided weight-loss drugs because they never wanted a shot, and the next few months will show how many of them actually fill a prescription.<\/p>\n
Related: Key HIV stat over 70% leaves BofA siding with Gilead<\/p>\n
#Lilly #gains #access #market #add #millions #customers<\/p>\n","protected":false},"excerpt":{"rendered":"
Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[2275,1820,516,567,11172,33,3573],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13518"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13518"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13518\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}